Foghorn Therapeutics (FHTX) to Release Quarterly Earnings on Thursday

Foghorn Therapeutics (NASDAQ:FHTX) will likely be posting its quarterly earnings results before the market opens on Thursday, March 6th. Analysts expect Foghorn Therapeutics to post earnings of ($0.43) per share and revenue of $8.56 million for the quarter.

Foghorn Therapeutics Trading Down 10.9 %

Shares of FHTX stock opened at $4.32 on Tuesday. Foghorn Therapeutics has a 12 month low of $3.86 and a 12 month high of $10.25. The company has a market capitalization of $240.24 million, a P/E ratio of -2.25 and a beta of 3.18. The stock has a 50 day moving average of $4.75 and a two-hundred day moving average of $6.78.

Analysts Set New Price Targets

Several brokerages recently commented on FHTX. Jefferies Financial Group reduced their target price on Foghorn Therapeutics from $18.00 to $14.00 and set a “buy” rating for the company in a research report on Monday, December 16th. HC Wainwright reaffirmed a “buy” rating and set a $13.00 price objective (down from $20.00) on shares of Foghorn Therapeutics in a report on Tuesday, December 17th. Finally, B. Riley started coverage on shares of Foghorn Therapeutics in a research note on Thursday, January 30th. They issued a “buy” rating and a $10.00 target price on the stock. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $13.17.

Foghorn Therapeutics Company Profile

Foghorn Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.